Boundless Historical Balance Sheet
BOLD Stock | USD 2.59 0.07 2.78% |
Trend analysis of Boundless Bio, Common balance sheet accounts such as Short Long Term Debt Total of 3.3 M, Other Current Liabilities of 2.6 M or Total Current Liabilities of 10 M provides information on Boundless Bio,'s total assets, liabilities, and equity, which is the actual value of Boundless Bio, Common to its prevalent stockholders. By breaking down trends over time using Boundless Bio, balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Boundless Bio, Common latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Boundless Bio, Common is a good buy for the upcoming year.
Boundless |
About Boundless Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Boundless Bio, Common at a specified time, usually calculated after every quarter, six months, or one year. Boundless Bio, Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Boundless Bio, and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Boundless currently owns. An asset can also be divided into two categories, current and non-current.
Boundless Bio, Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Boundless Bio, assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Boundless Bio, Common books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Boundless Bio, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Boundless Bio, Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most accounts from Boundless Bio,'s balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Boundless Bio, Common current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, Boundless Bio,'s Short and Long Term Debt Total is projected to decrease significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 10 M, whereas Total Stockholder Equity is projected to grow to (120.7 M).
2019 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 377K | 5.2M | 2.2M | 3.3M | Total Assets | 113.7M | 76.8M | 129.9M | 148.5M |
Boundless Bio, balance sheet Correlations
Click cells to compare fundamentals
Boundless Bio, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Boundless Bio, balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 178.7M | 472.6M | 113.7M | 76.8M | 129.9M | 148.5M | |
Short Long Term Debt Total | 7.2M | 7.1M | 377K | 5.2M | 2.2M | 3.3M | |
Other Current Liab | 3.7M | (2.0M) | 2.4M | 4.0M | 4.9M | 2.6M | |
Total Current Liabilities | 17.7M | 23.9M | 3.9M | 7.7M | 9.4M | 10.0M | |
Total Stockholder Equity | 156.6M | 442.8M | (38.2M) | (81.7M) | (127.1M) | (120.7M) | |
Property Plant And Equipment Net | 24.4M | 32.1M | 3.1M | 7.7M | 4.6M | 4.3M | |
Current Deferred Revenue | 5.6M | 7.7M | 2.2M | 3.9M | 3.5M | 3.6M | |
Net Debt | (31.8M) | (137.3M) | (33.9M) | (5.8M) | (21.5M) | (22.6M) | |
Retained Earnings | (190.6M) | (319.5M) | (40.8M) | (86.7M) | (136.1M) | (142.9M) | |
Accounts Payable | 3.9M | 8.1M | 1.1M | 1.4M | 2.2M | 2.5M | |
Cash | 39.0M | 144.3M | 34.3M | 11.0M | 23.7M | 38.5M | |
Non Current Assets Total | 41.7M | 52.8M | 39.1M | 8.8M | 5.7M | 5.4M | |
Non Currrent Assets Other | 3.1M | 6.4M | 1.1M | 533K | 555K | 527.3K | |
Cash And Short Term Investments | 133.6M | 414.3M | 73.0M | 66.7M | 120.8M | 121.8M | |
Short Term Investments | 94.6M | 270.0M | 38.7M | 55.8M | 97.0M | 83.3M | |
Liabilities And Stockholders Equity | 178.7M | 472.6M | 113.7M | 76.8M | 129.9M | 148.5M | |
Non Current Liabilities Total | 6.1M | 10.5M | 148.0M | 150.8M | 247.6M | 260.0M | |
Other Current Assets | 3.4M | 5.5M | 1.5M | 1.3M | 3.5M | 2.5M | |
Other Stockholder Equity | 47.3M | 462.3M | 2.8M | 5.4M | 9.0M | 8.5M | |
Total Liab | 22.1M | 29.8M | 151.9M | 158.5M | 257.0M | 269.8M | |
Total Current Assets | 137.0M | 419.8M | 74.6M | 68.0M | 124.2M | 124.3M | |
Accumulated Other Comprehensive Income | (80K) | (60K) | (175K) | (398K) | 40K | 42K | |
Short Term Debt | 4.6M | 2.3M | 377K | 2.3M | 2.2M | 2.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio, Common is a strong investment it is important to analyze Boundless Bio,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio,'s future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.